Depomed
Pharmaceutical Manufacturing • 
Newark, California, United States • 101-200 Employees
Company overview
| Headquarters | 7999 Gateway Blvd., Suite 300, Newark, CA 94560, US |
| Phone number | +12244197106 |
| Websites | |
| NAICS | 3254 |
| Keywords | Pharmaceutical, Neurology, Pain, Neuropathy, CNS, Nucynta |
| Founded | 1995 |
| Employees | 101-200 |
| Socials |
Key Contacts at Depomed
Yolanda Puga
Senior Director, Contract Manufacturing And Supply Chain
Angela Liu
Associate Director, Analytical Development
Sara Han
Associate Director Of Formulations
Sara Han
Associate Director Of Formulations
Tracy Chen
Director
Loren Foster
Sr. Director, Qa/Qc
Cuiping Chen
Director, Pharmacokinetics & Clinical Pharmacology
Andre Van Rensburg
Director
Jerry Yeh
Director
Mariel Pruneda
Executive Director
Depomed Email Formats
Depomed uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@depomed.com), used 90% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@depomed.com | 90% |
{last name}{last name} | doedoe@depomed.com | 10% |
About Depomed
Depomed is a leading specialty pharmaceutical company committed to putting the Patient First in everything we do; with a focus on enhancing the lives of patients, families, physicians, providers and in payors through commercialization of products in the areas of pain and neurology, and developing drugs in areas of unmet medical needs. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain Business and has an emerging Specialty Business focused on orphan drug indications and areas of unmet medical need. Depomed has a clear THREE PILLAR strategy for growth: MAINTAIN a strong/profitable NUCYNTA franchise through a commercialization agreement with Collegium, GROW the Neurology and Pain Business and BUILD a new Specialty Business through a recent Cosyntropin transaction. The company’s strategy is to continue to identify, license and develop new products-that offer enhanced therapeutic options to patient populations that may be underserved by existing therapies. As part of the transformation strategy, Depomed will be relocating its headquarters out of California. Information about location will be shared during the interview process. Depomed is listed on the NASDAQ market under the ticker DEPO. Depomed is an AA/EEO/Veterans/Disabled employer.
Depomed revenue & valuation
| Annual revenue | $300,000,000 |
| Revenue per employee | $2,190,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $960,000,000 |
| Total funding | $42,500,000 |
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
Depomed has 95 employees across 10 departments.
Departments
Number of employees
France
Israel
Italy
Frequently asked questions
4.8
40,000 users
